EUVIMEDEUVIMED entdecken
Vergleichsstudie

Comparison of lacosamide, levetiracetam, and valproate as second‐line therapy in adult status epilepticus: Analysis of a large cohort

Cecil D Hahn iD, Jan Novy iD, Andrea O Rossetti iD

Epilepsia · 2025-05 · 66 (5)

DOI: 10.1111/epi.18380 ↗

Kurz gefasst

Vergleichsstudie in der Zeitschrift Epilepsia, online erschienen am 22.03.2025. Verfasst von Cecil D Hahn und 2 weiteren Autor:innen. Beteiligte Einrichtung: Division of Neurology, The Hospital for Sick Children and Department of Paediatrics, University of Toronto, Toronto, Ontario, Canada. Hauptthemen laut MEDLINE: Levetiracetam, Lacosamide, Anticonvulsants, Status Epilepticus. Die Arbeit wurde bisher 8-mal zitiert (Crossref) und nennt 16 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

We compared the efficacy of lacosamide to other frequently used second‐line anti‐seizure medications (ASMs) for adult status epilepticus (SE) by conducting a retrospective analysis of an institutional SE registry between January 2013 and December 2022. Clinical outcomes assessed at discharge were categorized as return to baseline, new disability, or death; we also considered SE termination after the second‐line ASM and the need for mechanical ventilation. Potential confounders included the Status Epilepticus Severity Score (STESS), sex, adequacy of initial SE treatment, treatment delay, and potentially fatal etiology. Over 10 years, 961 adult SE episodes were analyzed; 868 were treated with the following second‐line ASMs: 413 levetiracetam (47.6%), 110 valproate (12.7%), and 75 lacosamide (8.6%), as well as lower rates of 18 other ASMs including benzodiazepines (not further analyzed). Univariable analysis identified STESS, treatment delay, and adequacy of initial SE treatment as potential confounders. On multivariable analysis adjusting for these variables, patients with episodes treated with second‐line lacosamide, levetiracetam, or valproate demonstrated statistically equivalent rates of seizure cessation, need for mechanical ventilation, and clinical outcomes at hospital discharge. We conclude that lacosamide appears to represent a reasonable alternative to levetiracetam and valproate, and warrants consideration for inclusion in future randomized controlled trials for control of SE.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

LevetiracetamLacosamideAnticonvulsantsStatus EpilepticusValproic AcidHumansMaleFemaleMiddle AgedRetrospective StudiesAdultAgedTreatment OutcomeCohort StudiesRegistries

Stichwörter der Autor:innen

anti‐seizure medicationcohort studycomparative studylacosamidestatus epilepticus

Substanzen

LevetiracetamLacosamideAnticonvulsantsValproic Acid

Autor:innen und Institutionen

  • Division of Neurology, The Hospital for Sick Children and Department of Paediatrics, University of Toronto, Toronto, Ontario, Canada.
  • Department of Clinical Neurosciences, Service de Neurologie, Centre Hospitalier Universitaire Vaudois (CHUV) and Lausanne University Hospital, Lausanne, Switzerland.

ORCID-Profile: Cecil D Hahn, Jan Novy, Andrea O Rossetti

Zitieren

APA

Hahn, C. D., Novy, J., & Rossetti, A. O. (2025). Comparison of lacosamide, levetiracetam, and valproate as second‐line therapy in adult status epilepticus: Analysis of a large cohort. Epilepsia, 66(5). https://doi.org/10.1111/epi.18380

Vancouver

Hahn CD, Novy J, Rossetti AO. Comparison of lacosamide, levetiracetam, and valproate as second‐line therapy in adult status epilepticus: Analysis of a large cohort. Epilepsia. 2025;66(5). doi:10.1111/epi.18380

BibTeX
@article{Hahn2025,
  author = {Hahn, Cecil D and Novy, Jan and Rossetti, Andrea O},
  title = {Comparison of lacosamide, levetiracetam, and valproate as second‐line therapy in adult status epilepticus: Analysis of a large cohort},
  journal = {Epilepsia},
  year = {2025},
  volume = {66},
  number = {5},
  doi = {10.1111/epi.18380}
}
Kostenlos starten →